PTEN and prostate carcinoma: GC was significantly more potent in inhibiting the growth of prostate cancer cells, with the IC50 values of 8.95 ± 0.92 μmol/L (LNCaP), 9.85 ± 2.60 μmol/L (DU145), 10.28 ± 0.79 μmol/L (PC-3), and 9.01 ± 0.15 μmol/L (PTEN-CaP8) compared with pancreas, colon, and breast cancer cells (Table1).